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OBJECTIVE: Salvia miltiorrhiza has long been used to treat systemic sclerosis. Tanshinone IIA, one of the
phytochemicals derived from the roots of Salvia miltiorrhiza, exhibits multiple biological activities. The present
study aimed to investigate whether tanshinone IIA has an effect on the interleukin-17A-induced functional
activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells.
METHODS: Systemic sclerosis patient-derived dermal vascular smooth muscle cells were incubated with various
dosages of tanshinone IIA in the presence of interleukin-17A or the serum of systemic sclerosis patients.
Cell proliferation was assessed using Cell Counting Kit-8. The expression of collagen 1 and 3 in cells was
evaluated by immunofluorescence. Cell migration was measured using a transwell assay. The expression of
phospho-extracellular signal-regulated kinase was detected by Western blotting.
RESULTS: Our data demonstrate that tanshinone IIA exerts an inhibitory effect on interleukin-17A-induced systemic
sclerosis patient-derived dermal vascular smooth muscle cell proliferation, collagen synthesis and migration.
CONCLUSION: These findings suggest that tanshinone IIA might serve as a promising therapeutic agent for the
treatment of systemic sclerosis.
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Systemic sclerosis (SSc) is a life-threatening connective
tissue disease characterized by autoimmunity, inflammation,
functional and structural alterations in small blood vessels
and vascular fibrosis of the skin and internal organs (1). SSc
has a complex pathogenesis and protean clinical manifesta-
tions that reflect immune dysregulation, microangiopathy
and systemic fibrosis, such as Raynaud phenomenon, digital
ulcers, pulmonary arterial hypertension and renal crisis
(2–4). Widespread intimal hypertrophy, a characteristic that
SSc shares with atherosclerosis, is the result of vascular
smooth muscle cell (myointimal cells) proliferation and
migration as well as local collagen accumulation (5). Vascular
smooth muscle cells play a crucial role in the development of
SSc-related vasculopathy.
T helper cell 17 (Th 17), a subset of T lymphocytes,
is implicated in the pathogenesis of SSc (6–10). Increased
levels of interleukin-17A (IL-17A)-producing CD4+ T cells
are observed in the lesional skin tissues and peripheral blood
of SSc patients (6). Our previous studies indicated increased
IL-17A in patients in the active phase of SSc. IL-17A
stimulates the expression of multiplex chemokines and
cellular adhesion molecules of vascular endothelial cells
and promotes collagen secretion from fibroblasts, resulting in
endothelial inflammation and fibrosis (9,10). Recently, our
unpublished data demonstrated that serum-derived IL-17A
from SSc patients promotes the proliferation, collagen
synthesis and migration of SSc patient-derived dermal
vascular smooth muscle cells (DVSMCs). Thus, we hypothe-
sized that the inhibition of the IL-17A-mediated activation of
DVSMCs may relieve the microangiopathy of SSc.DOI: 10.6061/clinics/2015(04)06
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Tanshinone IIA (C19H18O3) is a fat-soluble pharmacolo-
gically active component of the Chinese herb Salvia miltior-
rhiza, a well-known traditional Chinese medicine that is used
to treat cardiovascular diseases and connective tissue
diseases, such as systemic lupus erythematosus, SSc and
rheumatoid arthritis (11–17). Previous studies have demon-
strated that tanshinone IIA inhibits the proliferation and
migration of artery smooth muscle cells (18–24), reduces
pulmonary artery pressure and ameliorates hypoxia-induced
pulmonary artery remodeling (25). However, whether
tanshinone IIA can reverse the IL-17A-induced vessel
remodeling of SSc is not fully understood. In the present
study, we investigated whether tanshinone IIA inhibits
IL-17A-induced DVSMC proliferation, collagen synthesis
and migration.
’ MATERIALS AND METHODS
Ethics statement
This study was reviewed and approved by the Zhongshan
Hospital Research Ethics Committee. The Institutional
Review Board of Zhongshan Hospital of Fudan University
approved the human study protocol.
Reagents
Tanshinone IIA (99.0% pure; Boyun Biotech Company,
Shanghai, China) was prepared as a 10-mg/ml stock solution
in dimethyl sulfoxide and stored in the dark at  20˚C. The
following antibodies were used for immunofluorescence or
Western blotting: collagen 1, collagen 3 and a-smooth muscle
action (a-SMA) (Abcam, New York, USA). Myosin and
calponin were purchased from Proteintech Group, Inc.
(Chicago, USA). Glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH), p38, phospho-p38, Jun N-terminal kinase
(JNK), phospho-JNK, extracellular signal-regulated kinase
(ERK) and phospho-ERK were obtained from Cell Signaling
Technology (Boston, USA). Smooth muscle cell medium-basal
was obtained from Sciencell (San Diego, California, USA).
Human recombinant IL-17A was purchased from R&D
Systems (Minneapolis, Minnesota, USA). Other chemicals
and materials were obtained from the Beyotime Institute
of Biotechnology or KeyGEN Biotechnology Company
(Nanjing, China).
SSc patients and healthy individuals
Ten patients with SSc (n = 5 men and 5 women; mean age
42.9 ± 6.5 years) were enrolled in the study after providing
informed and written consent. All patients met the 1980
preliminary classification criteria for SSc (26). Disease activity
was assessed using the criteria proposed by Valentini et al.
(27), in which the evaluation of clinical and laboratory factors
are used to determine a score ranging from 0 to 10 (0
represents no disease activity, and 10 represents maximal
activity). Patients were in the active phase with scores Z 3,
and the disease durations were o 5 years. The patients had
different degrees of microangiopathy-related manifestations
(e.g., Raynaud phenomenon, digital ulcers, telangiectasia,
pulmonary hypertension and renal crisis). Ten age- and sex-
matched healthy individuals (n = 4 men and 6 women;
mean age 39.6 ± 5.3 years) were enrolled after providing
informed consent. Blood samples were obtained from SSc
patients and healthy individuals. Lesional skin tissues of SSc
patients were obtained to isolate DVSMCs.
Isolation and identification of SSc patient-derived
DVSMCs
DVSMCs were isolated from lesional skin tissues using the
trypsin digestion method. The cells were cultured with
smooth muscle cell medium-basal. DVSMCs from the third
to seventh passages were identified using immunofluo-
rescence staining for myosin and calponin. a-SMA was
analyzed by Western blotting. In addition, human primary
dermal vascular smooth muscle cells (HDVSMCs), which
were purchased from CHI Scientific, Inc. (Boston, USA),
served as a positive control. Both types of cells were cultured
at 37˚C with 5% CO2 and 100% humidity.
DVSMC culture and stimulation
The cells were seeded in 6-well plates at a density of
3  105 cells/well and cultured overnight. DVSMCs were
incubated with various dosages of tanshinone IIA (1, 10, and
100 mg/ml) in the presence of IL-17A (100 ng/ml) or 5%
serum from SSc patients or healthy subjects.
CCK-8
Cell proliferation was assessed using CCK-8. DVSMCs
were plated in 96-well plates at a density of 2  104 per well.
When cells were grown to 90 to 100% confluence, they were
stimulated for 24, 48 and 72 h. Then, 10 ml of the CCK-8
solution was added to each well 2 h prior to each time point,
and the optical density was read at 450 nm.
Cell fluorescence staining
Cells were plated in 24-well plates with cover slips. When
cells were grown to 90 to 100% confluence, they were
stimulated for 24 h. After stimulation, the cells were fixed
with 4% paraformaldehyde for 30 min and treated with 0.5%
triton for 15 min. The cells were blocked with 1% BSA for 30
min and incubated with rabbit anti-human collagen 1 (1:200)
and rabbit anti-human collagen 3 (1:300) overnight at 4˚C.
After incubation with FITC-goat anti-rabbit IgG at room
temperature for 1 h, DAPI (49,6-diamidino-2-phenylindole)
was used to stain the cell nuclei. The images were scanned
using a fluorescence microscope (Olympus, Japan).
Western blotting
Proteins from DVSMCs were extracted using RIPA lysis
buffer with the protease inhibitor phenylmethanesulfonyl
fluoride. Proteins were separated on 8% or 10% Tris-glycine
gels by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred onto polyvinylidene
fluoride (PVDF) membranes (Millipore, Billerica, MA, USA).
After blocking with 5% milk for 2 h at room temperature, the
membranes were incubated with primary antibodies, includ-
ing ERK, phospho-ERK, p38, phospho-p38, JNK, phospho-
JNK and GAPDH, overnight at 4˚C. The membranes were
washed and incubated with appropriate horseradish perox-
idase (HRP)-conjugated secondary antibodies for 1.5 h at
room temperature. The proteins were detected with ECL
detection reagents.
Transwell
DVSMC migration was evaluated using polycarbonate
membrane transwell chambers (8 mm pore size). The cells
that exhibited growth arrest for 48 h were harvested using
0.05% trypsin-EDTA solution and resuspended (10 
105 cells/ml) in the medium. The cells were added to the
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upper chamber. Tanshinone IIA (1, 10, and 100 mg/ml),
IL-17A (100 ng/ml), 5% healthy serum or 5% SSc serum were
added to the lower well of the chamber containing
Dulbecco's modified Eagle's medium with 2% serum. Cells
were incubated for 6 h at 37˚C and 5% CO2. After scraping
the cells affixed to the inside of the membrane, the cells that
had migrated through the insert were fixed with 4%
paraformaldehyde and stained with Giemsa according to
the manufacturer’s instructions. For each well, the number of
migrated cells was counted from 5 high-power fields (HPFs)
at 200 magnification.
Statistical analysis
Results were expressed as the mean ± SD values. The
statistical analysis was performed using SPSS 17.0 statistical
software (SPSS, Inc., Chicago, IL, USA). Statistical signifi-
cance was determined by analysis of variance for compar-
isons of multiple means followed by Student's t-test or the
Figure 1 - The identification of SSc patient-derived DVSMCs; tanshinone IIA inhibits IL-17A-induced DVSMC proliferation. (A) The
morphology and positive markers (Myosin, red fluorescence; Calponin, green fluorescence) of SSc patient-derived DVSMCs and
HDVSMCs are shown. Scale bars represent 100 mm. (B) a–SMA expression of SSc patient-derived DVSMCs and HDVSMCs was examined
by Western blotting. GAPDH was used as a loading control. (C) SSc patient-derived DVSMCs were treated with various dosages of
tanshinone IIA (1, 10, and 100 mg/ml) in the presence of human recombinant IL-17A (100 ng/ml) for 24, 48 and 72 h. Cell proliferation
(optical density) was assayed using CCK8. (D) DVSMCs were treated with various doses of tanshinone IIA in the presence of 5% serum
obtained from SSc patients or healthy subjects for 24, 48, and 72 h. Cell proliferation was assayed using CCK8. The data are presented as
the mean ± SD (standard deviation). The experiment was repeated three times.
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Mann-Whitney U test. Results demonstrating P o 0.05 were
considered statistically significant.
’ RESULTS
Tanshinone IIA inhibits IL-17A-induced proliferation
of SSc patient-derived DVSMCs
Our recent study demonstrated that a significant increase
in DVSMC proliferation occurred after incubation with 100
ng/ml IL-17A and SSc patient serum for 72 h compared with
the vehicle. In this study, we investigated the effect of
tanshinone IIA on IL-17A-induced DVSMC proliferation.
First, DVSMCs were isolated using the trypsin digestion
method and identified using immunofluorescence staining for
myosin and calponin (see Figure 1A). Furthermore, the
presence of a-SMA, a protein produced by DVSMCs, was
verified by Western blotting (see Figure 1B). In addition,
tanshinone IIA inhibited IL-17A-mediated DVSMC prolifera-
tion in a dose- and time-dependent manner (see Figure 1C). A
similar inhibition was observed in cells incubated with
tanshinone IIA in the presence of 5% SSc serum (see Figure 1D).
Tanshinone IIA attenuates IL-17A-induced collagen
synthesis in SSc patient-derived DVSMCs
Our recent study demonstrated that IL-17A derived from
the serum of SSc patients might play a role in inducing
collagen synthesis and secretion in DVSMCs. Here, we
demonstrate that tanshinone IIA inhibits the expression of
collagen 1 and 3 in the presence of IL-17A and 5% SSc serum
(see Figure 2A and B). These results indicate that tanshinone
IIA might play a role in attenuating IL-17A-induced collagen
synthesis in DVSMCs.
Tanshinone IIA suppresses IL-17A-induced
migration of SSc patient-derived DVSMCs
In scleroderma, an increased number of vascular smooth
muscle cells migrate from media to intima, resulting in
intimal thickening and vascular stenosis. In the present
study, IL-17A and SSc serum promoted DVSMC migration.
Tanshinone IIA significantly reduced the number of migrat-
ing cells in the presence of IL-17A and 5% SSc serum
(see Figure 3A and B).
Tanshinone IIA reduces IL-17A-induced ERK
phosphorylation in SSc patient-derived DVSMCs
The above results indicate that tanshinone IIA attenuated
IL-17A-induced DVSMC proliferation, collagen synthesis and
migration. However, the precise mechanism underlying these
effects has not been established. Recently, we discovered that
ERK MAPK might be an important signaling pathway in
the IL-17A-induced up-regulation of DVSMC proliferation,
Figure 2 - Tanshinone IIA attenuates IL-17A-induced collagen synthesis in SSc patient-derived DVSMCs. (A) DVSMCs were treated with
tanshinone IIA (100 mg/ml) in the presence of IL-17A (100 ng/ml) and 5% serum from SSc patients or healthy subjects for 24 h. Collagen
1 was detected by immunofluorescence. (B) DVSMCs were treated with tanshinone IIA (100 mg/ml) in the presence of IL-17A (100 ng/ml)
and 5% serum from SSc patients or healthy subjects for 24 h. Collagen 3 was stained by immunofluorescence. The experiment was
repeated three times.
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collagen synthesis and migration. We detected phospho-ERK,
phospho-JNK and phospho-p38 MAPK in these cells. We found
that tanshinone IIA inhibited ERK phosphorylation induced by
IL-17A or 5% SSc serum. However, JNK and p38 phosphoryla-
tion was not significantly altered (see Figure 4A-D).
’ DISCUSSION
In the present study, we demonstrated that tanshinone IIA
inhibits IL-17A-induced proliferation and migration as well
as collagen synthesis in SSc patient-derived DVSMCs. Further-
more, we indicate that tanshinone IIA reduced ERK phos-
phorylation stimulated by IL-17A and SSc serum in a time- and
dose-dependent manner. This novel information partially
clarified the mechanism by which tanshinone IIA ameliorates
IL-17A-induced vascular remodeling in SSc patients.
Although advances have been made in the treatment of
SSc, targeted therapies with fewer side effects are still
lacking. Our previous studies have demonstrated the
therapeutic efficacy of Salvia miltiorrhiza on SSc (28–30).
Tanshinone IIA is one of the pharmacological components
of Salvia miltiorrhiza. Recently, tanshinone IIA has been
shown to modulate the growth, proliferation and migration
of numerous cells, including keratinocytes, cardiac fibro-
blasts, cardiomyocytes, tumor cells and human aortic
smooth muscle cells (20,31–39). IL-17A-induced aberrant
Figure 3 - Tanshinone IIA suppresses IL-17A-induced migration of SSc patient-derived DVSMCs. (A) DVSMCs were incubated
with tanshinone IIA (100 mg/ml) in the presence of IL-17A (100 ng/ml) or 5% serum from SSc patients or healthy subjects for 24 h.
Cell migration was measured via the transwell assay. Black arrows represent migrated cells per high-power field (HPF) at
200 magnification. Scale bar = 100 mm. (B) The number of migrated cells per HPF. The experiment was repeated three times, and data
are presented as the mean ± SD.
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vascular smooth muscle cell proliferation may serve as
a major cause of vascular remodeling. Therefore, we
hypothesized that the inhibition of IL-17A-induced vascular
smooth muscle cell proliferation might contribute to its anti-
remodeling effects. The present study demonstrated
that tanshinone IIA significantly inhibited IL-17A-induced
DVSMC proliferation.
In our recent study, we demonstrated that human
recombinant IL-17A and SSc serum-derived IL-17A promoted
collagen 1 and 3 synthesis and secretion in SSc patient-derived
DVSMCs. Here, the immunofluorescence results indicated
that tanshinone IIA reduces collagen 1 and collagen 3
synthesis in DVSMCs when co-stimulated with human
recombinant IL-17A or SSc serum-derived IL-17A.
Similarly, our previous transwell experiments revealed
that IL-17A and SSc serum-derived IL-17A accelerated
DVSMC migration. Our present results revealed that
tanshinone IIA decreased the number of migrating cells in
the presence of IL-17A and SSc serum.
The above results indicate that tanshinone IIA inhibits
IL-17A-induced abnormal DVSMC activation. However, the
exact mechanism remains unknown. ERK, a member of the
MAPK family, is the core of the signal transduction pathway
networks involved in regulating cell growth, development
and division (40). Data from our recent study implied that
the ERK signaling pathway might play a key role in IL-17A-
induced endothelial injury and vascular smooth muscle cell
activation (10). In the current study, we found that
tanshinone IIA decreased IL-17A-induced phospho-ERK in
a time- and dose-dependent manner. These results indicate
that tanshinone IIA might affect IL-17A-induced prolifera-
tion, collagen synthesis and migration of SSc patient-derived
DVSMCs via inhibition of the ERK signaling pathway.
In summary, our results provide preliminary evidence that
tanshinone IIA exerts an inhibitory effect on IL-17A-induced
proliferation, collagen synthesis and migration of SSc
patient-derived DVSMCs. This inhibitory effect may be
dependent on the ERK MAPK signaling pathway.
These collective findings potentially explain why Salvia
miltiorrhiza clearly relieves symptoms in SSc patients in the
clinic. These findings suggest that tanshinone IIA might
serve as a promising therapeutic agent for SSc patients.
However, the current results require validation with further
studies.
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Figure 4 - Tanshinone IIA reduces IL-17A-induced ERK phosphorylation in SSc patient-derived DVSMCs. (A) DVSMCs were treated with
tanshinone IIA (100 mg/ml) in the presence of IL-17A (100 ng/ml) for 15, 30, 45 and 60 min, and the phosphorylation of ERK, JNK and
p38 MAPK were detected by western blotting. (B) DVSMCs were exposed to tanshinone IIA (100 mg/ml) in the presence of SSc serum for
15, 30, 45 and 60 min. The phosphorylation of ERK was detected by western blotting. (C) DVSMCs were incubated with different
dosages of tanshinone IIA (1 mg/ml, 10 mg/ml, 100 mg/ml) in the presence of IL-17A (100 ng/ml) for 30 min. The phosphorylation of ERK
was detected by western blotting. (D) DVSMCs were incubated with different dosage of tanshinone IIA (1, 10, and 100 mg/ml) for 30
min in the presence of SSc serum. The phosphorylation of ERK was detected by western blotting. GAPDH was used as a loading control.
The experiment was repeated three times.
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